csl brazil biostate human coagulation factor viii (post clinical trial supply) 500 iu / von willebrand factor 1200 iu powder for injection vial with diluent
csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, solution - excipient ingredients: water for injections - biostate is indicated for: - the treatment and prophylaxis of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. - the treatment and prophylaxis of bleeding associated with fviii deficiency due to haemophilia a.
csl malaysia aleviate human coagulation factor viii 500iu/von willebrand factor 1200iu complex, powder for injection (50iu/ml fviii)
csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: water for injections - aleviate is indicated for: ? the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.
csl malaysia aleviate human coagulation factor viii 250iu/von willebrand factor 600iu complex, powder for injection (50iu/ml fviii)
csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: water for injections - aleviate is indicated for: ? the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.
csl hong kong biostate human coagulation factor viii 250iu/von willebrand factor 500iu complex, powder for injection (50iu/ml fviii)
csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - biostate is indicated for: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. - the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.
brancico xl 300mg tablets
zentiva pharma uk ltd - quetiapine fumarate - modified-release tablet - 300mg
brancico xl 200mg tablets
zentiva pharma uk ltd - quetiapine fumarate - modified-release tablet - 200mg
brancico xl 150mg tablets
zentiva pharma uk ltd - quetiapine fumarate - modified-release tablet - 150mg
brancico xl 50mg tablets
zentiva pharma uk ltd - quetiapine fumarate - modified-release tablet - 50mg
brancico xl 400mg tablets
zentiva pharma uk ltd - quetiapine fumarate - modified-release tablet - 400mg
membrane, internal, tympanic
medtronic australasia pty ltd - 34410 - membrane, internal, tympanic - the device is intended for use as a protective cover of a clean, dry perforation in a dry ear.